Date: 2011-05-02
Type of information: Company acquisition
Acquired company: Nordic Vaccine (Denmark)
Acquiring company: Isconova (Sweden)
Amount: SEK 4,032,228 (€ 446 600)
Terms: The purchase price amounts to SEK 4,032,228 (€ 446 600) and is paid via a new issue of 120 365 Isconova shares to a price of SEK 33.50 (€ 3.7) per share, corresponding to a dilution of about 3 percent of the total number of outstanding shares in Isconova. At the same time Nordic Vaccine commits to buying a new issue of Isconova shares to an amount of SEK 873,504 to a price of SEK 33.70 per share, corresponding to a dilution of 0.6 percent of the total number of outstanding shares in Isconova. The proceeds from this new share issue will cover costs for maintenance and administration of the acquired patent family for the coming years. The total dilution amounts to 3.6 percent and the total number of outstanding shares in Isconova will amount to 4 158 452.
Details: Isconova has acquires the assets of Nordic Vaccine A/S, a Danish research and development company specialised in adjuvants and drug delivery development. The acquisition will significantly strengthen Isconova’s patent position within vaccine systems and adjuvant technology. Nordic Vaccine’s product portfolio includes the Posintro®-technology which is closely related to Isconovas Matrix®-technology as well as a preclinical platform for needle free administration of vaccines through a dermal patch system.
Related: Vaccines
